#Sweden #Epigenica #EpiFinder #GenomePro #Solna

Epigenica AB Introduces EpiFinder™ GenomePro

A Revolutionary Tool for Comprehensive Epigenomic Exploration

Epigenica AB has proudly announced the launch of its innovative product, EpiFinder™ GenomePro, which represents a significant leap in epigenomic research capabilities. This cutting-edge platform is designed to empower researchers by allowing them to explore the intricate landscape of post-translational histone modifications (hPTM) and DNA methylation simultaneously, thereby achieving unmatched high throughput and cost-effectiveness while maintaining exceptional data quality.

The EpiFinder™ GenomePro, a next-generation iteration of the previous EpiFinder™ Genome, comes equipped with optimized reagents and streamlined protocols, enabling researchers to analyze 24 samples in a single run. This advancement not only facilitates robust quantitative data for 192 genome-wide chromatin immunoprecipitation sequencing (ChIP-Seq) profiles for multiple hPTMs and DNA methylation but also requires minimal sample volumes. The key advantage of a lower cost per sample makes large-scale studies more accessible than ever.

Flexible Design and Unprecedented Analysis Transparency

The design of the EpiFinder™ GenomePro is notably flexible, allowing researchers to select hPTMs regardless of DNA methylation. This adaptability is crucial as it responds to specific research needs without compromising data integrity. Furthermore, the open-source data analysis process ensures optimized analyses, providing unmatched transparency and reproducibility.

Mohamad Takwa, the CEO of Epigenica AB, states, "With EpiFinder™ GenomePro, we are setting a new standard in epigenomic research. Our vision is to create a platform that delivers valuable insights, enabling researchers to tackle complex biological questions with unprecedented scale and depth."

Transforming Therapeutic Research

EpiFinder™ GenomePro is poised to significantly impact therapeutic research by unlocking insights into the epigenetic mechanisms underlying disease onset and progression while also predicting patient treatment responses. By providing extensive and high-resolution epigenomic data, this revolutionary tool allows scientists to discover new biomarkers, map complex pathological processes, and generate valuable insights that underpin the development of targeted precision therapies.

Moreover, EpiFinder™ GenomePro is an ideal kit for laboratories with limited prior experience in ChIP-seq or similar methodologies, making it feasible for them to obtain high-quality ChIP-seq data without considerable time investment. Björn Reinius, Associate Professor at the Karolinska Institute, commented, "With minimal optimization, the protocol allows users to generate quantitative ChIP-seq libraries and conduct preliminary data analyses effortlessly."

Commitment to Advancing Epigenomic Research

Epigenica AB is committed to equipping researchers with the tools necessary to produce high-performance, multiplexed, and quantifiable data efficiently, paving the way for broader knowledge in epigenomics.

To discover how EpiFinder™ GenomePro can transform your research capabilities, visit Epigenica AB’s website at www.epigenica.se.

About Epigenica

Founded in Stockholm, Sweden, in 2020, Epigenica is at the forefront of life science technology innovation in epigenetic research. Its EpiFinder platform enables comprehensive epigenetic studies to be conducted with unprecedented speed, scalability, and affordability. The company is developing a range of products based on the EpiFinder platform to provide high-performance profiles with varying levels of detail and a wide variety of starting materials. Backed by patented high-throughput, multiplexed quantitative ChIP-seq technology, Epigenica is instrumental in advancing biomedical research, drug discovery and development, precision medicine, and therapies targeting aging and longevity.